Maximizing Commercial Outcomes for Oncology Medicines

We see what’s possible and bring it to market

Recent News & Events

View All
Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma Jun 09, 2025 Press Release
Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting Dec 09, 2024 Press Release
Back to top